Autopsy report · NCT04127721

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

“0 ACTUAL Enrollment must have Overall Recruitment Status”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Allogeneic Stem Cell Transplant Recipient; Hematologic and Lymphocytic Disorder; Hematopoietic and Lymphoid Cell Neoplasm

Interventions

Allogeneic Hematopoietic Stem Cell Transplantation; Busulfan; Fludarabine; Itacitinib; Methotrexate; Tacrolimus

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Metformin as an Upstream Therapy in Atrial Fibrillation
  “Recruitment issue: Enrollment expectation not met” (68% match in meaning)
• Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
  “Low recruitment/enrollment” (67% match in meaning)
• Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
  “Low subject recruitment and enrollment.” (66% match in meaning)
• Intraosseous Basivertebral Nerve Ablation for Treatment of Chronic Low Back Pain
  “No Enrollments” (66% match in meaning)
• Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes
  “insufficient recruitment/enrollment” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.